利妥昔单抗联合CHOP方案在非霍奇金淋巴瘤临床应用效果分析  

Clinical Effect of Rituximab Combined with CHOP Regimen in Treatment of Non-hodgkin's Lymphoma

作　　者：李葳[1] 

机构地区：[1]福建医科大学附属三明第一医院,福建三明365000

出　　处：《中外医学研究》2017年第13期11-13,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:分析利妥昔单抗联合CHOP方案(泼尼松、环磷酰胺、长春新碱、多柔比星)在非霍奇金淋巴瘤临床应用效果及不良反应的发生率。方法:收集从2011年6月-2014年12月在笔者所在医院就诊的48例NHL患者的临床资料,将48例患者随机分为对照组和试验组,每组24例,对照组患者采用CHOP治疗方案(泼尼松、环磷酰胺、长春新碱、多柔比星),试验组患者在上述治疗的基础上联合应用利妥昔单抗,对比分析两组患者临床治疗效果及不良反应的发生状况,并对患者进行随访,统计分析中位生存时间。结果:在对照组中,进展患者3例,稳定患者6例,部分缓解患者8例,完全缓解患者7例,总有效率为62.5%;而在试验组中,进展患者1例,稳定患者2例,部分缓解患者11例,完全缓解患者10例,总有效率为87.5%,差异有统计学意义(P<0.05)。两组患者呕吐恶心、心电图异常、肝功能损害、血小板减少、白细胞减少、脱发等不良反应发生情况比较差异无统计学意义(P>0.05)。对照组患者中位生存时间为26个月,而在试验组患者中位生存时间为32个月,试验组延长时间较为显著,差异有统计学意义(P<0.05)。结论:利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤临床效果显著增加,并且患者不良反应的发生率并没有增加,能够显著延长患者的中位生存时间,在临床中具有推广和应用的价值。Objective： To analyze the clinical effect of Rituximab combined with CHOP regimen in Non-Hodgkin＇s Lymphoma and the incidence of adverse reactions.Method： From June 2011 to December 2014 in the author＇s hospital, 48 cases of NHL patients with clinical data were selected and randomly divided into control group and experimental group, each group of 24 patients, the control group Patients were treated with CHOP regimen（prednisone, cyclophosphamide, vincristine, doxorubicin）, the experimental group of patients on the basis of the above treatment combined rituximab, clinical efficacy, incidence condition of adverse reaction, and the median survival time of the patients were compared.Result： In the control group, 3 patients progressed, 6 patients were stable, 8 patients with partial remission, 7 patients completed remission, the total effective rate was 62.5%, while in the experimental group, 1 patient progressed, 2 patients were stable, 11 patients with partial remission, 10 patients completed remission, the total effective rate was 87.5%, the difference was statistically significant（P〈0.05）.There were no significant differences in vomiting and nausea, ECG abnormality, liver function damage, thromboeytopenia, ieukopenia and alopecia in the two groups（P〉0.05）.The median survival time was 26 months in the control group and 32 months in the experimental group, and the prolongation time was significant.Conclusion： Rituximab combined with CHOP regimen in the treatment of Non-Hodgkin＇s Lymphoma has a significant increase in clinical efficacy, and the incidence of adverse reactions has not increased, and can significantly prolong the median survival time in patients with clinical promotion And the value of the application.

关 键 词：非霍奇金淋巴瘤 利妥昔单抗 CHOP方案 临床效果 不良反应 

分 类 号：R733.1[医药卫生—肿瘤]